[an error occurred while processing this directive] | [an error occurred while processing this directive]
Preliminary study of neoadjuvant plus chemotherapy combined with concurrent chemoradiotherapy for locally advanced giant cervical cancer
Yang Hua1, Wei Lichun1, Zhang Ying1, Zhang Jianjun2, Yin Yutian1, Zhou Yan1, Shi Mei1
1Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China; 2Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China
AbstractObjective To preliminarily investigate the efficacy and safety of bevacizumab plus neoadjuvant chemotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced giant cervical cancer (LACC). Methods Twenty-four patients with LACC who were treated with bevacizumab combined with neoadjuvant chemotherapy were assigned into the study group, and 30 patients receiving neoadjuvant chemotherapy in phase Ⅱ clinical trial (ChiCTR-TRC-11001832) were allocated in the control group. The survival rate was calculated by the Kaplan-Meier method, and the significance of differences between the variables was determined by the log-rank test. Results The tumor volumes were (1.64±23.15) cm3 and (12.83±15.08)(P=0.037), and the complete remission (CR) rates were calculated as 45.8% and 13.3%(P=0.004) in the study and control groups after neoadjuvant chemotherapy. The tumor volumes were (0±1.5) cm3 and (1.00±10.63) cm3(P=0.022) and the CR rates were 70% and 50%(P=0.009) in the study and control groups before afterloading treatment. The median follow-up was 24.6(9.3-101.7) months. The 1-and 2-year overall survival rates were 96%,96% and 90%,71%(P=0.110),the recurrence-free survival rates was 96%,96% and 97%,89%(P=0.512),and the distant metastasis-free survival rates were 96%, 88% and 83%,80%(P=0.297) in the study and control groups, respectively. Adverse reactions were acceptable in both groups. Conclusion Bevacizumab combined with neoadjuvant chemotherapy can significantly reduce the tumor volume, improve the tumor CR rate and yield tolerable adverse reactions.
Corresponding Authors:
Shi Mei, Email:mshi82@fmmu.edu.cn
Cite this article:
Yang Hua,Wei Lichun,Zhang Ying et al. Preliminary study of neoadjuvant plus chemotherapy combined with concurrent chemoradiotherapy for locally advanced giant cervical cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 372-375.
Yang Hua,Wei Lichun,Zhang Ying et al. Preliminary study of neoadjuvant plus chemotherapy combined with concurrent chemoradiotherapy for locally advanced giant cervical cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 372-375.
[1] Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer:an update of radiation therapy oncology group trial (RTOG) 90-01[J]. J Clin Oncol, 2004, 22(5):872-880. DOI:10.1200/JCO.2004.07.197. [2] Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol, 2000, 18(8):1606-1613. DOI:10.1200/JCO.2000.18.8.1606. [3] Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340(15):1144-1153. DOI:10.1056/NEJM199904153401502. [4] Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix:a systematic review and meta-analysis[J]. Lancet, 2001, 358(9284):781-786. DOI:10.1016/S0140-6736(01)05965-7. [5] Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer:a systematic review and meta-analysis of individual patient data from 18 randomized trials[J]. J Clin Oncol,2008,26(35):5802-5812. DOI:10.1200/JCO.2008.16.4368. [6] Wang N, Li WW, Li JP, et al. Comparison of concurrent chemoradiotherapy followed by radical surgery and high-dose-rate intracavitary brachytherapy:a retrospective study of 240 patients with FIGO stage ⅡB cervical carcinoma[J]. Onco Targets Ther, 2014, 7:91-100. DOI:10.2147/OTT. S52710. [7] Narayan K, Fisher R, Bernshaw D. Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy[J]. Int J Gynecol Cancer, 2006, 16(2):623-630. DOI:10.1111/j.1525-1438.2006.00379.x. [8] Monk BJ, Sill MW, Burger RA, et al. Phase Ⅱ trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix:a gynecologic oncology group study[J]. J Clin Oncol, 2009, 27(7):1069-1074. DOI:10.1200/JCO.2008.18.9043. [9] Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370(8):734-743. DOI:10.1056/NEJMoa1309748. [10] Harsh KK, Kapoor A, Paramanandhan M, et al. Induction chemotherapy followed by concurrent chemoradiation in the management of different stages of cervical carcinoma:5-year retrospective study[J]. J Obstet Gynaecol India, 2016, 66(5):372-378. DOI:10.1007/s13224-015-0699-4. [11] Narayan S, Sharma N, Kapoor A, et al. Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer:a regional cancer center experience[J]. J Obstet Gynaecol India, 2016, 66(5):385-390. DOI:10.1007/s13224-015-0698-5. [12] Pötter R, Tanderup K, Kirisits C, et al. The EMBRACE Ⅱ study:the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies[J]. Clin Transl Radiat Oncol, 2018, 9(1):48-60. DOI:10.1016/j.ctro.2018.01.001. [13] Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer:Analysis from the retro EMBRACE study[J]. Radiother Oncol, 2016, 120(3):434-440. DOI:10.1016/j.radonc.2016.03.020. [14] Jastaniyah N, Yoshida K, Tanderup K, et al. A volumetric analysis of GTV (D) and CTV (HR) as defined by the GEC ESTRO recommendations in FIGO stage ⅡB and ⅢB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE)[J]. Radiother Oncol, 2016, 120(3):404-411. DOI:10.1016/j.radonc.2016.05.029. [15] Schefter T, Winter K, Kwon JS, et al. RTOG 0417:efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014, 88(1):101-105. DOI:10.1016/j.ijrobp.2013.10.022.
2021, Vol. 30 
